Advancements in drug delivery for hyperpigmentation: emerging therapies and future prospects

This review emphasizes the significance of emerging drug delivery technologies and explores potential avenues for future dermatological treatments.

Hyperpigmentation is a prevalent skin condition characterized by dark patches due to excessive melanin production. Various forms, such as melasma, post-inflammatory hyperpigmentation, and UV induced pigmentation, arise from a complex interplay of genetic factors, inflammation, hormonal fluctuations, and light exposure. While conventional topical treatments, including azelaic acid, retinoids, hydroquinone, and kojic acid, remain effective, their use is often limited by adverse effects like skin irritation, blistering, and sensitivity. To address these challenges, advanced drug delivery systems have been developed to improve therapeutic efficacy, enhance formulation stability, and enable targeted delivery, thereby minimizing potential side effects.

Advanced vesicular carriers, including liposomes, niosomes, lipid nanoparticles, and nano-emulsions, offer enhanced drug penetration, bioavailability, and reduced toxicity. However, achieving sustained results and preventing recurrence remain critical challenges in hyperpigmentation management. Recent advancements in personalized treatment strategies and novel delivery methods provide promising solutions for safer and more effective therapies. Additionally, procedural interventions such as chemical peels and micro-needling have demonstrated encouraging results in managing chronic hyperpigmentation.